Is It Time To Revisit DexCom (DXCM) After Share Price Weakness And DCF Upside?
- Wondering if DexCom at around US$61.63 is starting to look interesting again, or if the stock still carries too much downside risk for your portfolio?
- The share price has inched up about 1.7% over the past week and 0.7% over the past month, but is still down about 7.4% year to date and has declined about 27.9% over the past year.
- Recent headlines have focused on DexCom’s role in continuous glucose monitoring and how that fits into broader healthcare technology trends, which can shape how investors view its growth potential. At the same time, changing sentiment around higher growth healthcare stocks has also influenced how the market prices DexCom’s future prospects.
- Right now DexCom scores a 4/6 valuation check score. The next sections…
Source link
